[PDF] Top 20 Narración de Historias en Psicoterapia Infantil
Has 10000 "Narración de Historias en Psicoterapia Infantil" found on our website. Below are the top 20 most common "Narración de Historias en Psicoterapia Infantil".
Treatment options for paediatric pulmonary arterial hypertension
... to treatment can be difficult to quantify in ...of treatment and follow-up procedures are predefined has not been applied to children but it could be used to tailor PAH therapy to individual ...and ... See full document
25
Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
... for using a selective ET A receptor antagonist, which include blocking the vasoconstrictive and proliferative effects of endothelin-1 at the ET A receptor, while at the same time preserving the potentially beneficial ... See full document
10
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
... the treatment of ...to treatment with ...and pulmonary vascular resistance (p 5 ...embolic pulmonary hypertension) study was completed recently ...mediated pulmonary vascular ... See full document
11
Pulmonary hypertension
... thromboembolic pulmonary hypertension (CTEPH) was ...the treatment of PAH, relatively little is known about the optimal strategy for combining ...with Pulmonary Arterial ... See full document
67
The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective
... intravenous treatment, a process of education, monitoring and support is ...if treatment outcomes are to be ...the treatment of ...the pulmonary hypertension clinical team, especially ... See full document
6
Platelet derived growth factor receptor β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno occlusive disease: a case control study
... PDGFR-b, its ligand and its phosphorylated state and EGFR were observed in plexiform lesions of IPAH patients. Their active participation in plexiform lesion formation remains speculative, but Perros et al. [33] ... See full document
11
Palliative care in pulmonary arterial hypertension: an underutilised treatment
... Anxiety is augmented by the patients ’ limited knowledge regarding PAH, including the uncertainties regarding treatment and prognosis. Many patients and caregivers resort to finding information on the internet. ... See full document
10
Pulmonary arterial hypertension
... ongoing treatment (sequen- tial combination) or in first intention by starting from the beginning with a combination ...in pulmonary vascular resistance was greater with combination therapy, al- though it ... See full document
261
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
... Without treatment, PAH is a relentlessly progressive ...modern treatment era ...and treatment, for the majority of patients with PAH, disease progression is inevitable and long-term survival remains ... See full document
73
Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
... the treatment of PAH patients in FC II and FC III at the WTP ...line treatment for PAH FC II and FC III in the benefits package even though the medicine is not registered for PAH treatment in ... See full document
6
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
... Broad treatment guidelines apply to all patients with ...potent pulmonary vasoconstrictor, and it is advisable for oxygen to be administered to maintain saturations above ...mean pulmonary artery ... See full document
21
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
... on pulmonary angiography, acute PE appears as a floating clot in the pulmonary artery surrounded by ...the pulmonary arterial wall and is characterised by the presence of fibrous scars that ... See full document
36
Pulmonary arterial hypertension: tailoring treatment to risk in the current era
... significant improvements in WHO FC, exercise capacity and haemodynamics from baseline to month 4. These data illustrate the benefits of dual combination therapy targeting the endothelin and nitric oxide (NO) pathways and ... See full document
14
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
... In the GRIPHON trial, the distribution of the final attained dosing range was 200–400 μ g twice daily in 23%, 600– 1,000 μ g twice daily in 31%, and 1,200–1,600 μ g twice daily in 43% of patients. Interestingly, in a ... See full document
10
Epoprostenol sodium for treatment of pulmonary arterial hypertension
... increase the dose weekly or monthly to the maximal tolerated dose based on clinical symptoms and side effects in individual cases. We adjust the dose to match the change in body weight. Epoprostenol has a short ... See full document
20
The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
... The dose and duration of the latest iron chelator before bosentan were also recorded. The mean levels of hemoglobin and ferritin were calculated for 6 months before bosentan administration. The patients were asked about ... See full document
31
Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease
... mean pulmonary artery pressures and pulmonary vascular resistance, and improved cyanosis and functional capacity, in patients with Eisenmenger syndrome (n57) ... See full document
67
Ambrisentan for the treatment of pulmonary arterial hypertension
... ambrisentan treatment), 48% of patients were receiving the maximal dose of ambrisentan (10 mg) and no additional elevations of alanine aminotrans- ferase (ALT) or aspartate aminotransferase (AST) 3 times ULN were ... See full document
20
Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation
... with pulmonary veno-occlusive disease (PVOD), a severe condition that is clinically similar to PAH [56], and pulmonary capillary haemangiomatosis have the worst prognosis and should be referred for ... See full document
21
Macitentan for the treatment of pulmonary arterial hypertension
... The duration of the trial allowed for a comprehensive assessment of the adverse-effect profile of macitentan. Given macitentan’s structural relationship to bosentan, there was great interest in its effects on ... See full document
52
Related subjects